SDGR

Over the past six months, Schrödinger, Inc.'s stock price has been impacted by several key events, including a significant decrease of 45.06% over the last 12 months. In Q1 2026, revenue exceeded expectations, but statutory losses widened, leading to adjusted revenue and loss forecasts. The announced acquisition of Ajax Therapeutics by Lilly, in which Schrödinger held an equity stake, was highlighted as a validation of Schrödinger's platform. The upcoming launch of "Bunsen" is drawing early excitement. The company is accelerating its transition to a hosted software licensing model, impacting near-term software revenue recognition but expected to lead to durable ACV growth. Analysts have adjusted their price targets downwards, reflecting concerns about near-term revenue pressure. Schrödinger shares fell after the company filed a proxy seeking shareholder approval to add 3 million shares to its 2022 Equity Incentive Plan.